预防呼吸道合胞病毒感染导致的住院治疗。
Preventing hospitalizations for respiratory syncytial virus infection.
作者信息
Robinson Joan L, Le Saux Nicole
出版信息
Paediatr Child Health. 2015 Aug-Sep;20(6):321-33. doi: 10.1093/pch/20.6.321.
Abstract
Respiratory syncytial virus infection is the leading cause of lower respiratory tract infections in young children. Palivizumab has minimal impact on RSV hospitilization rates as it is only practical to offer it to the highest risk groups. The present statement reviews the published literature and provides updated recommendations regarding palivizumab use in children in Canada.
摘要
呼吸道合胞病毒感染是幼儿下呼吸道感染的主要原因。帕利珠单抗对呼吸道合胞病毒住院率的影响极小，因为仅对最高风险群体使用该药物才具有实际意义。本声明回顾了已发表的文献，并提供了关于加拿大儿童使用帕利珠单抗的最新建议。
相似文献
1
Preventing hospitalizations for respiratory syncytial virus infection.预防呼吸道合胞病毒感染导致的住院治疗。
Paediatr Child Health. 2015 Aug-Sep;20(6):321-33. doi: 10.1093/pch/20.6.321.
2
Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection.呼吸道合胞病毒感染住院风险增加的婴幼儿使用帕利珠单抗预防的更新指南。
Pediatrics. 2014 Aug;134(2):415-20. doi: 10.1542/peds.2014-1665.
3
4
Prophylaxis in RSV infection (Palivizumab)--is it worthwhile?呼吸道合胞病毒感染的预防（帕利珠单抗）——是否值得？
Ir Med J. 2000 Dec;93(9):284.
5
Preventing respiratory syncytial virus infections.预防呼吸道合胞病毒感染。
Paediatr Child Health. 2011 Oct;16(8):487-90. doi: 10.1093/pch/16.8.487.
6
Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection.呼吸道合胞病毒感染住院风险增加的婴幼儿使用帕利珠单抗预防的更新指南。
Pediatrics. 2014 Aug;134(2):e620-38. doi: 10.1542/peds.2014-1666.
7
Palivizumab Prophylaxis in Infants and Young Children at Increased Risk of Hospitalization for Respiratory Syncytial Virus Infection.帕利珠单抗预防高风险住院的婴幼儿呼吸道合胞病毒感染。
Pediatrics. 2023 Jul 1;152(1). doi: 10.1542/peds.2023-061803.
8
Updated cost-effectiveness analysis of palivizumab (Synagis) for the prophylaxis of respiratory syncytial virus in infant populations in the UK.英国婴儿人群使用帕利珠单抗（Synagis）预防呼吸道合胞病毒的成本效果更新分析。
J Med Econ. 2020 Dec;23(12):1640-1652. doi: 10.1080/13696998.2020.1836923. Epub 2020 Oct 27.
9
Monoclonal antibody for reducing the risk of respiratory syncytial virus infection in children.用于降低儿童呼吸道合胞病毒感染风险的单克隆抗体。
Cochrane Database Syst Rev. 2013 Apr 30(4):CD006602. doi: 10.1002/14651858.CD006602.pub4.
10
Palivizumab: a review of its use as prophylaxis for serious respiratory syncytial virus infection.帕利珠单抗：作为预防严重呼吸道合胞病毒感染药物的应用综述
Paediatr Drugs. 2004;6(3):177-97. doi: 10.2165/00148581-200406030-00004.
引用本文的文献
1
Respiratory Syncytial Virus Burden in Premature Infants: The Role of Season With and Without RSV Immunoprophylaxis in a Multicenter Study.早产儿呼吸道合胞病毒负担：一项多中心研究中有无呼吸道合胞病毒免疫预防措施情况下季节因素的作用
Pediatr Pulmonol. 2025 Mar;60(3):e71022. doi: 10.1002/ppul.71022.
2
RSV vaccination as the optimal prevention strategy for older adults.呼吸道合胞病毒疫苗接种作为老年人的最佳预防策略。
Infez Med. 2024 Dec 1;32(4):478-488. doi: 10.53854/liim-3204-6. eCollection 2024.
3
Opinion: The optimal use of risk factors to guide palivizumab prophylaxis against severe respiratory syncytial virus infection in moderate-to-late preterm infants.观点：利用风险因素指导帕利珠单抗预防中度至晚期早产儿严重呼吸道合胞病毒感染的最佳方法
Front Pediatr. 2024 Jan 12;12:1343960. doi: 10.3389/fped.2024.1343960. eCollection 2024.
4
The rapidly changing landscape of respiratory syncytial virus prophylaxis.呼吸道合胞病毒预防领域迅速变化的局面。
J Assoc Med Microbiol Infect Dis Can. 2023 Nov 29;8(3):165-171. doi: 10.3138/jammi-2023-05-31. eCollection 2023 Nov.
5
For Indigenous infants, RSV prevention is better than a cure.对于原住民婴儿来说，预防呼吸道合胞病毒比治疗更有效。
Nature. 2023 Sep;621(7980):S68. doi: 10.1038/d41586-023-02963-1.
6
The palivizumab patchwork: Variation in guidelines for Respiratory Syncytial Virus prevention across Canadian provinces and territories.帕利珠单抗的拼凑情况：加拿大各省和地区呼吸道合胞病毒预防指南的差异
Paediatr Child Health. 2020 Feb 20;26(2):e115-e120. doi: 10.1093/pch/pxz166. eCollection 2021 Apr-May.
7
Palivizumab Prophylaxis for infants 29 to 32 weeks gestation at birth: A 10-year audit from Vancouver Island using BC Guidelines.帕利珠单抗对出生时孕周为29至32周的婴儿的预防作用：一项基于不列颠哥伦比亚省指南、来自温哥华岛的10年审计。
Paediatr Child Health. 2020 Feb 4;26(2):e110-e114. doi: 10.1093/pch/pxz151. eCollection 2021 Apr-May.
8
Follow-up care of the extremely preterm infant after discharge from the neonatal intensive care unit.新生儿重症监护病房出院后极早产儿的随访护理
Paediatr Child Health. 2022 Oct 3;27(6):359-371. doi: 10.1093/pch/pxac058. eCollection 2022 Oct.
9
Urgent air transfers for acute respiratory infections among children from Northern Canada, 2005-2014.2005-2014 年加拿大北部儿童急性呼吸道感染的紧急空运。
PLoS One. 2022 Jul 28;17(7):e0272154. doi: 10.1371/journal.pone.0272154. eCollection 2022.
10
Evaluating the Individual Healthcare Costs and Burden of Disease Associated with RSV Across Age Groups.评估与 RSV 相关的各年龄段个体医疗保健成本和疾病负担。
Pharmacoeconomics. 2022 Jun;40(6):633-645. doi: 10.1007/s40273-022-01142-w. Epub 2022 May 13.
本文引用的文献
1
Respiratory syncytial virus infections in pediatric transplant recipients: A Canadian Paediatric Surveillance Program study.儿科移植受者中的呼吸道合胞病毒感染：一项加拿大儿科监测项目研究。
Pediatr Transplant. 2015 Sep;19(6):659-62. doi: 10.1111/petr.12553. Epub 2015 Jul 7.
2
Efficacy and optimization of palivizumab injection regimens against respiratory syncytial virus infection.帕利珠单抗注射方案抗呼吸道合胞病毒感染的疗效及优化
JAMA Pediatr. 2015 Apr;169(4):341-8. doi: 10.1001/jamapediatrics.2014.3804.
3
Effectiveness of Palivizumab in Preventing RSV Hospitalization in High Risk Children: A Real-World Perspective.帕利珠单抗预防高危儿童呼吸道合胞病毒住院的有效性：一项真实世界视角的研究。
Int J Pediatr. 2014;2014:571609. doi: 10.1155/2014/571609. Epub 2014 Dec 4.
4
Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection.呼吸道合胞病毒感染住院风险增加的婴幼儿使用帕利珠单抗预防的更新指南。
Pediatrics. 2014 Aug;134(2):415-20. doi: 10.1542/peds.2014-1665.
5
Palivizumab for prophylaxis against respiratory syncytial virus infection in children with cystic fibrosis.帕利珠单抗用于预防囊性纤维化患儿的呼吸道合胞病毒感染。
Cochrane Database Syst Rev. 2014 May 22(5):CD007743. doi: 10.1002/14651858.CD007743.pub5.
6
Respiratory syncytial virus disease in preterm infants in the U.S. born at 32-35 weeks gestation not receiving immunoprophylaxis.美国孕32 - 35周出生且未接受免疫预防的早产儿的呼吸道合胞病毒病
Pediatr Infect Dis J. 2014 Jun;33(6):576-82. doi: 10.1097/INF.0000000000000219.
7
Hospitalization for respiratory syncytial virus illness in Down syndrome following prophylaxis with palivizumab.帕利珠单抗预防治疗后唐氏综合征患者因呼吸道合胞病毒病住院治疗。
Pediatr Infect Dis J. 2014 Feb;33(2):e29-33. doi: 10.1097/INF.0000000000000019.
8
The cost of lower respiratory tract infections hospital admissions in the Canadian Arctic.加拿大北极地区下呼吸道感染住院治疗的费用。
Int J Circumpolar Health. 2013 Aug 5;72. doi: 10.3402/ijch.v72i0.21595. eCollection 2013.
9
Respiratory syncytial virus and recurrent wheeze in healthy preterm infants.呼吸道合胞病毒与健康早产儿反复喘息
N Engl J Med. 2013 May 9;368(19):1791-9. doi: 10.1056/NEJMoa1211917.
10
Potential for palivizumab interference with commercially available antibody-antigen based respiratory syncytial virus diagnostic assays.帕利珠单抗可能会干扰市售的基于抗体-抗原的呼吸道合胞病毒诊断检测。
Pediatr Infect Dis J. 2013 Oct;32(10):1144-6. doi: 10.1097/INF.0b013e31829561dd.
Zotero 插件